Navigation Links
Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
Date:10/17/2007

Decision Facilitates European Trial Opening in 13 New Sites

BERKELEY HEIGHTS, N.J., Oct. 17 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced that the French Health Products Safety Agency ("AFSSAPS") has granted authorization to open the Company's Phase 3 trial of Genasense(R) (oblimersen sodium) Injection, its lead anticancer compound, in patients with advanced melanoma. This authorization enables the opening of approximately 13 new investigative sites over the next 2-4 weeks.

Genta's Phase 3 trial, known as AGENDA, is a randomized, double-blind, placebo-controlled study in which patients are randomly assigned to receive Genasense plus dacarbazine (DTIC) or DTIC alone. AGENDA will accrue approximately 300 patients and will be conducted at approximately 100 sites worldwide, including North America, Europe and Australia. Accrual, which is currently ongoing, is currently expected to complete in the fourth quarter of 2008.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two major programs: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodi
'/>"/>

SOURCE Genta Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014  Perrigo Company plc ... global provider of "Quality Affordable Healthcare Products®," today announced ... relating to the sale of 6,809,210 ordinary shares at ... the full exercise of the option to purchase up ... Securities LLC and Barclays Capital Inc., as representatives of ...
(Date:11/26/2014)... Texas , Nov. 26, 2014 ... today announced the completion of previously announced concurrent ... million.  After fees and estimated offering expenses, Lexicon ... the transactions.  The transactions consisted of: ... common stock, pursuant to a registration statement that ...
(Date:11/26/2014)... Md. , Nov. 26, 2014  Over 100 ... of those suffer from this pain daily. Chronic and ... of pain management is born to fulfill the need ... all types of pain. On October 28th, ... the Cumberland, Maryland community.  This ...
Breaking Medicine Technology:Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3New Pain Management Center Opens in Cumberland, Md. 2
... CITY, Calif., Jan. 4, 2011 Arstasis is pleased ... to physicians, nurses, patients, and cath lab technicians across ... of physicians participating in Arstasis clinical trials and select ...  As of today, the company is making the simple-to-use, ...
... 4, 2011 Isis Pharmaceuticals, Inc. (Nasdaq: ... Recent Advances in Isis, Development PipelineWhen: , Thursday, ... 9:00 a.m. PTWhere: , www.isispharm.comHow: , Live on ... listed above. Contacts: , Kristina LemonidisDirector, Investor Relations(760) ...
Cached Medicine Technology:Nationwide Launch of Arstasis One Access Device Provides Cath Labs Across the U.S. an Alternative to Standard Arteriotomies and Vascular Closure Implants 2
(Date:11/28/2014)... An inventor and dental assistant from Kent, Wash., was ... it was almost impossible to reach. "This gave me the ... The patent-pending Access Light allows for easier use of a ... mouth, as well as avoids harm to the lips, tongue ... and clean, it also helps prevent cross-contamination. , The original ...
(Date:11/28/2014)... York, New York (PRWEB) November 28, 2014 ... ( http://www.consumerinjurylawyers.com/stryker-rejuvenate/stryker-hip-lawsuits/ ) have now been filed in ... of recalled metal implants, Bernstein Liebhard LLP reports. ... 18th in Bergen County Superior Court reflects the ... ABG II modular-neck hip stems, which were voluntarily ...
(Date:11/28/2014)... Lice Troopers Lice Removal Service is pleased ... head lice service for moms in Miami-Dade County. Lice Troopers ... Gables on Pone De-leon Blvd in Miami. The company ... service Miami-Dade & Broward. Lice Troopers is the only Lice ... has been treating families for several years. , Lice Troopers ...
(Date:11/28/2014)... November 28, 2014 An inventor from Flint, ... to day. "I got this idea while lying in a ... bathroom," he said. , The Bed Buddy provides a more ... to the bathroom. It eliminates the need to leave the ... comfort and dignity. Easy to use and producible in design ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 ARTAS robotic ... for the first time. PAI Medical Group hair transplant ... be performing a robotic hair transplant procedure in the ... A.M. , The first in Tennessee and one of ... Group now offers ARTAS robotic hair transplantation. Patients benefit ...
Breaking Medicine News(10 mins):Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 2Health News:More than 2,100 Stryker Hip Lawsuits Included in New Jersey Litigation after Settlement Announcement, Bernstein Liebhard LLP Reports 3Health News:Lice Troopers Lice Removal Service Expands in Miami-Dade 2Health News:First in Tennessee - PAI Medical Group Announces ARTAS - The World’s Most Advanced Medical Robot Used for Hair Transplant Surgery 2
... treatments down the road, researchers say , WEDNESDAY, May ... geneticists have identified a genetic mutation that appears to ... most common major birth defect. , Congenital heart disease ... compared to diseases like cancer, according to study author ...
... food industry is ,trying to do the right thing, researcher ... removing harmful trans fats from foods would open the door ... foods seem to be unfounded, a new study finds. , ... reformulated products from supermarkets and restaurants, and found little cause ...
... University Hospitals has been designated as a Neuroscience Center ... Excellence Survey sponsored by NeuStrategy, Inc., Chicago. It ... the Stage 4 Institute designation. The ... in the neurosciences and is the industry standard for ...
... levels of hormone that triggers the need for a night,s ... 26 (HealthDay News) -- Brain injuries can disrupt the body,s ... a new study suggests. , "We,ve known that people often ... haven,t known much about the exact causes of these problems," ...
... under trade name Xenical and over-the-counter as Alli , ... of rare but sometimes severe cases of liver damage, ... a widely used weight-loss drug. , The drug, orlistat, ... and over-the-counter as Alli. , Thirteen cases of severe ...
... of individualized therapies, experts say , WEDNESDAY, May 26 (HealthDay ... two, but potentially tens of thousands of genetic mutations which, ... sample from a lung tumor from a heavy smoker revealed ... issue of Nature . , "People in the field ...
Cached Medicine News:Health News:Gene Mutation Linked to Congenital Heart Disease 2Health News:Healthier Fats Replacing Trans Fats, Study Finds 2Health News:Healthier Fats Replacing Trans Fats, Study Finds 3Health News:University Hospitals Neurological Institute earns Neuroscience Center of Excellence designation 2Health News:Brain Injuries May Lead to Sleep Woes 2Health News:Rare Cases of Liver Damage Tied to Weight-Loss Drug 2Health News:Rare Cases of Liver Damage Tied to Weight-Loss Drug 3Health News:Single Lung Tumor Contains 50,000 Mutations 2
... Features exclusive micro-prism refractive technology that ... distributed light onto the surgical site. ... unmatched combination of cavity illumination, shadow ... representation. The highly maneuverable PrismAlix Series ...
Flat tip, bare fiber, no cooling, polished SMA 905, 3 meters long. Sold in boxes of five. Each part is individually packaged in sterile Tyvek bags....
One piece, 100% fused silica construction offers low scatter and high efficiency...
Stirrups provide a safe system for positioning patients in a variety of lithotomy positions. Power-assisted positioning, as well as abduction, assures proper positioning of the patient. Includes one ...
Medicine Products: